Berman Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Berman Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$15K	Buy	934 +230	+33%	+$3.86K	﹤0.01%	1074
2021 Q2	$11K	Sell	704 -406	-37%	-$6.91K	﹤0.01%	1120
2021 Q1	$20K	Buy	1,110 +99	+10%	+$1.78K	﹤0.01%	802
2020 Q4	$18K	Sell	1,011 -129	-11%	-$2.26K	﹤0.01%	708
2020 Q3	$20K	Buy	1,140 +103	+10%	+$1.88K	0.01%	589
2020 Q2	$17K	Buy	1,037 +523	+102%	+$9.39K	﹤0.01%	598
2020 Q1	$7K	Sell	514 -200	-28%	-$3.63K	﹤0.01%	802
2019 Q4	$14K	Sell	714 -39	-5%	-$746	﹤0.01%	637
2019 Q3	$12K	Buy	753 +341	+83%	+$5.9K	﹤0.01%	670
2019 Q2	$7K	Sell	412 -275	-40%	-$5K	﹤0.01%	875
2019 Q1	$14K	Buy	+687	New	+$13.8K	﹤0.01%	559

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berman Capital Advisors's TAK Position: Q3 2021 in Review

Berman Capital Advisors increased its Takeda Pharmaceutical (TAK) stake by 33% in Q3 2021, buying an estimated $3.86K and bringing the position to 934 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1074.

Berman Capital Advisors first reported a position in TAK in Q1 2019 and has held it in 11 quarters since. The position peaked at $20K in Q1 2021. 293 funds tracked by Wall St. Rank hold TAK as of Q3 2021.

Berman Capital Advisors held 934 shares of Takeda Pharmaceutical worth $15K as of Q3 2021.
Berman Capital Advisors bought 230 Takeda Pharmaceutical shares in Q3 2021, an estimated $3.86K.
Takeda Pharmaceutical made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1074 holding.
Berman Capital Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 11 quarters since.
Berman Capital Advisors's Takeda Pharmaceutical position peaked at $20K in Q1 2021.
293 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.